Biogen Inc. $BIIB Shares Acquired by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. raised its holdings in Biogen Inc. (NASDAQ:BIIB) by 313.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,855 shares of the biotechnology company’s stock after acquiring an additional 2,165 shares during the period. TD Waterhouse Canada Inc.’s holdings in Biogen were worth $645,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Bell Investment Advisors Inc acquired a new position in Biogen during the 2nd quarter worth approximately $27,000. Ashurst Perkins Coie Trust Co boosted its position in Biogen by 92.2% in the third quarter. Ashurst Perkins Coie Trust Co now owns 173 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 83 shares in the last quarter. Triumph Capital Management boosted its position in Biogen by 20,800.0% in the third quarter. Triumph Capital Management now owns 209 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 208 shares in the last quarter. Cassaday & Co Wealth Management LLC acquired a new stake in Biogen in the first quarter valued at approximately $40,000. Finally, Maryland Capital Advisors Inc. grew its stake in shares of Biogen by 21,900.0% during the third quarter. Maryland Capital Advisors Inc. now owns 220 shares of the biotechnology company’s stock worth $50,000 after buying an additional 219 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Trading Up 5.3%

Shares of BIIB stock opened at $253.84 on Friday. Biogen Inc. has a fifty-two week low of $138.00 and a fifty-two week high of $254.41. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. The stock has a 50 day simple moving average of $222.78 and a two-hundred day simple moving average of $205.73. The company has a market cap of $37.50 billion, a P/E ratio of 44.93, a PEG ratio of 2.68 and a beta of 0.09.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. The firm had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The company’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the prior year, the business earned $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Research analysts forecast that Biogen Inc. will post 12.31 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on BIIB shares. HSBC upped their price target on shares of Biogen from $165.00 to $175.00 and gave the stock a “reduce” rating in a report on Thursday, September 10th. Needham & Company LLC raised their price objective on Biogen from $255.00 to $256.00 and gave the company a “buy” rating in a report on Monday, June 29th. HC Wainwright boosted their price objective on Biogen from $237.00 to $251.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Seaport Research Partners raised Biogen to an “outperform” rating in a report on Monday, October 12th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Biogen in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $241.89.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Wells Fargo raised its price target on Biogen, adding to a series of upward analyst revisions and reinforcing optimism about the company’s outlook. Biogen Stock Gets Price Target Boost from Wells Fargo
• Positive Sentiment: Bank of America increased its Biogen price target to $244 from $219. Although the firm maintained a Neutral rating, the revision reflects improved expectations as analysts update their models ahead of earnings. Biogen on BofA Price Target Hike
• Positive Sentiment: Several previews suggest Biogen could exceed third-quarter earnings estimates, supported by favorable analyst expectations and the potential for continued progress across its late-stage drug pipeline. Biogen Expected to Beat Earnings Estimates
• Neutral Sentiment: Wedbush kept a Hold rating on Biogen, indicating that valuation and near-term catalysts may already be reflected in the share price. Wedbush Remains a Hold on Biogen
• Negative Sentiment: Bank of America’s $244 target remains below the stock’s recent trading level, implying limited upside or potential downside despite the target increase. Analysts also characterize the upcoming quarter as relatively quiet, and earnings previews warn that disappointment remains possible.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.